CytoDyn Initiates Pre-Clinical Study of Leronlimab (PRO 140) to Prevent NASH with The Cleveland Clinic's Dr. Daniel J. Lindner, M.D., Ph.D.

Stock Information for CytoDyn Inc

Loading

Please wait while we load your information from QuoteMedia.